- Home
- NBIX vs XPO Comparison
NBIX vs XPO Comparison
Compare NBIX & XPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- XPO
- Stock Information
- Founded
- NBIX 1992
- XPO 2000
- Country
- NBIX United States
- XPO United States
- Employees
- NBIX N/A
- XPO N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- XPO Transportation Services
- Sector
- NBIX Health Care
- XPO Consumer Discretionary
- Exchange
- NBIX Nasdaq
- XPO Nasdaq
- Market Cap
- NBIX 13.2B
- XPO 15.3B
- IPO Year
- NBIX 1996
- XPO N/A
- Fundamental
- Price
- NBIX $128.91
- XPO $118.73
- Analyst Decision
- NBIX Strong Buy
- XPO Strong Buy
- Analyst Count
- NBIX 22
- XPO 18
- Target Price
- NBIX $165.59
- XPO $137.83
- AVG Volume (30 Days)
- NBIX 935.9K
- XPO 1.1M
- Earning Date
- NBIX 07-30-2025
- XPO 07-31-2025
- Dividend Yield
- NBIX N/A
- XPO N/A
- EPS Growth
- NBIX 2.97
- XPO N/A
- EPS
- NBIX 3.39
- XPO 2.89
- Revenue
- NBIX $2,509,900,000.00
- XPO $8,009,000,000.00
- Revenue This Year
- NBIX $16.12
- XPO $0.45
- Revenue Next Year
- NBIX $15.06
- XPO $4.07
- P/E Ratio
- NBIX $38.04
- XPO $41.11
- Revenue Growth
- NBIX 18.42
- XPO N/A
- 52 Week Low
- NBIX $84.23
- XPO $85.06
- 52 Week High
- NBIX $157.98
- XPO $161.00
- Technical
- Relative Strength Index (RSI)
- NBIX 46.34
- XPO 34.98
- Support Level
- NBIX $130.75
- XPO $133.25
- Resistance Level
- NBIX $137.44
- XPO $141.57
- Average True Range (ATR)
- NBIX 3.60
- XPO 4.48
- MACD
- NBIX -0.71
- XPO -1.79
- Stochastic Oscillator
- NBIX 33.88
- XPO 1.68
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About XPO XPO Inc.
Following the spinoff of its contract logistics division (GXO) in 2021 and freight brokerage operations (RXO) in 2022, XPO is moving closer to becoming a pure-play asset-based less-than-truckload carrier. We estimate LTL shipping makes up 60% of total revenue, with XPO's European truckload and LTL operations making up 40%. However, XPO's LTL segment EBITDA mix is much higher than 60%. We believe XPO intends to divest its European trucking division once it finds the right buyer.